Psoriatic Arthritis - Pipeline Review, H1 2014 @ http://www.researchmoz.us/psoriatic-arthritis-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Psoriatic Arthritis - Pipeline Review, H1 2014
Psoriatic Arthritis - Pipeline Review, H1 2014
Summary
Global Markets Directs, Psoriatic Arthritis - Pipeline Review, H1 2014, provides an overview of the Psoriatic Arthritiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and
discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company
and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 8
list Of Figures 9
introduction 10
global Markets Direct Report Coverage 10
psoriatic Arthritis Overview 11
therapeutics Development 12
pipeline Products For Psoriatic Arthritis - Overview 12
pipeline Products For Psoriatic Arthritis - Comparative Analysis 13
psoriatic Arthritis - Therapeutics Under Development By Companies 14
psoriatic Arthritis - Pipeline Products Glance 17
late Stage Products 17
clinical Stage Products 18
early Stage Products 19
Psoriatic Arthritis - Pipeline Review, H1 2014

2. unknown Stage Products 20
psoriatic Arthritis - Products Under Development By Companies 21
psoriatic Arthritis - Companies Involved In Therapeutics Development 23
alcon, Inc. 23
bristol-myers Squibb Company 24
amgen Inc. 25
eli Lilly And Company 26
celltrion, Inc. 27
biocon Limited 28
pfizer Inc. 29
ucb S.a. 30
sandoz Inc. 31
celgene Corporation 32
swedish Orphan Biovitrum Ab 33
panacea Biotec Limited 34
viropro Inc. 35
alder Biopharmaceuticals Inc. 36
coronado Biosciences, Inc. 37
kineta, Inc. 38
avesthagen Limited 39
covagen Ag 40
shanghai Celgen Bio-pharmaceutical Co., Ltd. 41
biosidus S.a. 42
genor Biopharma Co., Ltd. 43
forward Pharma A/s 44
inbiopro Solutions Pvt. Ltd. 45
innovent Biologics, Inc. 46
epirus Biopharmaceuticals, Inc. 47
alphamab Co., Ltd 48
pharmapraxis 49
psoriatic Arthritis - Therapeutics Assessment 50
assessment By Monotherapy Products 50
assessment By Target 51
assessment By Mechanism Of Action 54
assessment By Route Of Administration 57
assessment By Molecule Type 59
drug Profiles 61
apremilast - Drug Profile 61
product Description 61
mechanism Of Action 61
r&d Progress 61
secukinumab - Drug Profile 63
product Description 63
mechanism Of Action 63
r&d Progress 63
certolizumab Pegol - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
infliximab Biosimilar - Drug Profile 72
product Description 72
mechanism Of Action 72
r&d Progress 72
infliximab Biosimilar - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
brodalumab - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
ixekizumab - Drug Profile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
tofacitinib - Drug Profile 78
product Description 78
mechanism Of Action 78
Psoriatic Arthritis - Pipeline Review, H1 2014

3. r&d Progress 78
secukinumab - Drug Profile 82
product Description 82
mechanism Of Action 82
r&d Progress 82
abatacept - Drug Profile 85
product Description 85
mechanism Of Action 85
r&d Progress 85
infliximab Biosimilar - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
adalimumab Biosimilar - Drug Profile 89
product Description 89
mechanism Of Action 89
r&d Progress 89
clazakizumab - Drug Profile 90
product Description 90
mechanism Of Action 90
r&d Progress 90
dimethyl Fumarate - Drug Profile 92
product Description 92
mechanism Of Action 92
r&d Progress 92
shk-186 - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
infliximab Biosimilar - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
adalimumab Biosimilar - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
adalimumab Biosimilar - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
itolizumab - Drug Profile 98
product Description 98
mechanism Of Action 98
r&d Progress 98
tso - Drug Profile 100
product Description 100
mechanism Of Action 100
r&d Progress 100
etanercept Biosimilar - Drug Profile 102
product Description 102
mechanism Of Action 102
r&d Progress 102
adalimumab Biosimilar - Drug Profile 103
product Description 103
mechanism Of Action 103
r&d Progress 103
etanercept Biosimilar - Drug Profile 104
product Description 104
mechanism Of Action 104
r&d Progress 104
ibpm-005-ix - Drug Profile 105
product Description 105
mechanism Of Action 105
r&d Progress 105
ibpm-004-am - Drug Profile 106
product Description 106
mechanism Of Action 106
Psoriatic Arthritis - Pipeline Review, H1 2014

4. r&d Progress 106
etanercept Biosimilar - Drug Profile 107
product Description 107
mechanism Of Action 107
r&d Progress 107
cova-322 - Drug Profile 108
product Description 108
mechanism Of Action 108
r&d Progress 108
etanercept Biosimilar - Drug Profile 109
product Description 109
mechanism Of Action 109
r&d Progress 109
adalimumab Biosimilar - Drug Profile 110
product Description 110
mechanism Of Action 110
r&d Progress 110
etanercept Biosimilar - Drug Profile 111
product Description 111
mechanism Of Action 111
r&d Progress 111
adalimumab Biosimilar - Drug Profile 112
product Description 112
mechanism Of Action 112
r&d Progress 112
ibi-303 - Drug Profile 113
product Description 113
mechanism Of Action 113
r&d Progress 113
nd-007 - Drug Profile 114
product Description 114
mechanism Of Action 114
r&d Progress 114
infliximab Biosimilar - Drug Profile 115
product Description 115
mechanism Of Action 115
r&d Progress 115
etanercept Biosimilar - Drug Profile 116
product Description 116
mechanism Of Action 116
r&d Progress 116
adalimumab Biosimilar - Drug Profile 117
product Description 117
mechanism Of Action 117
r&d Progress 117
inv-17 - Drug Profile 118
product Description 118
mechanism Of Action 118
r&d Progress 118
anakinra - Drug Profile 119
product Description 119
mechanism Of Action 119
r&d Progress 119
adalimumab Biosimilar - Drug Profile 120
product Description 120
mechanism Of Action 120
r&d Progress 120
infliximab Biosmiliar - Drug Profile 121
product Description 121
mechanism Of Action 121
r&d Progress 121
etanercept Biosimilar - Drug Profile 122
product Description 122
mechanism Of Action 122
r&d Progress 122
etanercept Biosimilar - Drug Profile 123
product Description 123
mechanism Of Action 123
Psoriatic Arthritis - Pipeline Review, H1 2014

5. r&d Progress 123
psoriatic Arthritis - Recent Pipeline Updates 124
psoriatic Arthritis - Dormant Projects 162
psoriatic Arthritis - Discontinued Products 163
psoriatic Arthritis - Product Development Milestones 164
featured News & Press Releases 164
jan 22, 2014: Stelara (ustekinumab) Receives Health Canada Approval For Treatment Of Active Psoriatic Arthritis 164
oct 29, 2013: Oral Apremilast Monotherapy Demonstrated Long-term Clinical Benefits In Psoriatic Arthritis Patients Nave To Previous Dmard Therapy 165
oct 28, 2013: Oral Apremilast Demonstrated Clinically Meaningful And Statistically Significant Improvements In Enthesitis And Dactylitis 166
oct 28, 2013: New Stelara Data Show Inhibition Of Joint Destruction In Patients With Active Psoriatic Arthritis 168
oct 25, 2013: Ucb-sponsored Data On Cimzia To Be Highlighted At 2013 American College Of Rheumatology Annual Scientific Meeting 171
oct 24, 2013: Chmp Adopts Positive Opinion For Ucb Pharma's Cimzia 173
sep 30, 2013: Cimzia Approved By The U.s. Fda For Treatment Of Adult Patients With Active Psoriatic Arthritis 174
sep 26, 2013: New Long-term Apremilast Data To Be Presented At American College Of Rheumatology Annual Meeting 175
sep 23, 2013: Stelara (ustekinumab) Receives Fda Approval To Treat Active Psoriatic Arthritis 178
sep 23, 2013: Stelara Receives European Commission Approval For Treatment Of Active Psoriatic Arthritis 179
appendix 182
methodology 182
coverage 182
secondary Research 182
primary Research 182
expert Panel Validation 182
contact Us 183
disclaimer 183
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Psoriatic Arthritis - Pipeline Review, H1 2014